{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:41:56Z","timestamp":1783521716074,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41409-022-01658-x","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T06:03:07Z","timestamp":1649138587000},"page":"1010-1012","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center"],"prefix":"10.1038","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2679-975X","authenticated-orcid":false,"given":"Alexander D.","family":"Heini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Kronig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2259-1011","authenticated-orcid":false,"given":"Gertrud","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urban","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sacha","family":"Zeerleder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrouz","family":"Mansouri Taleghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Daskalakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-5257","authenticated-orcid":false,"given":"Thomas","family":"Pabst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"1658_CR1","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML. Mantle cell lymphoma. J Clin Oncol. 2016;34:1256\u201369.","journal-title":"J Clin Oncol"},{"key":"1658_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.leukres.2015.03.004","volume":"39","author":"MD Berger","year":"2015","unstructured":"Berger MD, Branger G, Leibundgut K, Baerlocher GM, Seipel K, Mueller BU, et al. CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma. Leuk Res. 2015;39:561\u20137.","journal-title":"Leuk Res"},{"key":"1658_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/hon.2197","volume":"34","author":"MD Berger","year":"2016","unstructured":"Berger MD, Branger G, Klaeser B, Taleghani BM, Novak U, Banz Y, et al. Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma. Hematol Oncol. 2016;34:133\u20139.","journal-title":"Hematol Oncol"},{"key":"1658_CR4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","volume":"26","author":"CY Cheah","year":"2015","unstructured":"Cheah CY, Chihara D, Romaguera JE, Fowler NH, Seymour JF, Hagemeister FB, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26:1175\u20139.","journal-title":"Ann Oncol"},{"key":"1658_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"1658_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45\u201356.","journal-title":"N Engl J Med"},{"key":"1658_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2019-124750","volume":"134","author":"MC Pasquini","year":"2019","unstructured":"Pasquini MC, Locke FL, Herrera AF, Siddiqi T, Ghobadi A, Komanduri KV, et al. Post-marketing use outcomes of an Anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood 2019;134:764.","journal-title":"Blood"},{"key":"1658_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2019-130983","volume":"134","author":"S Jaglowski","year":"2019","unstructured":"Jaglowski S, Hu Z-H, Zhang Y, Kamdar M, Ghosh M, Lulla P, et al. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B-Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 2019;134:766.","journal-title":"Blood"},{"key":"1658_CR9","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","volume":"38","author":"LJ Nastoupil","year":"2020","unstructured":"Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: Results from the US lymphoma CAR T consortium. J Clin Oncol. 2020;38:3119\u201328.","journal-title":"J Clin Oncol"},{"key":"1658_CR10","first-page":"629","volume":"386","author":"MR Bishop","year":"2021","unstructured":"Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-hodgkin lymphoma: analysis of the phase III belinda study. Blood 2021;386:629\u201339.","journal-title":"Blood"},{"key":"1658_CR11","doi-asserted-by":"publisher","unstructured":"Messmer AS, Que Y-A, Schankin C, Banz Y, Bacher U, Novak U, et al. CAR T-cell therapy and critical care. Wien Klin Wochenschr [Internet]. 2021; Available from: https:\/\/doi.org\/10.1007\/s00508-021-01948-2","DOI":"10.1007\/s00508-021-01948-2"},{"key":"1658_CR12","doi-asserted-by":"crossref","unstructured":"Messmer AS, Que Y-A, Schankin C, Banz Y, Bacher U, Novak U, et al. Novel Adaptive T-Cell Oncological Treatments Lead to New Challenges for Medical Emergency Teams: A 2-Year Experience From a Tertiary-Care Hospital in Switzerland. Crit Care Explor [Internet]. 2021;3. Available from: https:\/\/journals.lww.com\/ccejournal\/Fulltext\/2021\/10000\/Novel_Adaptive_T_Cell_Oncological_Treatments_Lead.15.aspx","DOI":"10.1097\/CCE.0000000000000552"},{"key":"1658_CR13","doi-asserted-by":"publisher","first-page":"7-14.e3","DOI":"10.1016\/j.exphem.2020.07.003","volume":"88","author":"T Pabst","year":"2020","unstructured":"Pabst T, Joncourt R, Shumilov E, Heini A, Wiedemann G, Legros M, et al. Analysis of IL-6 serum levels and CAR T cell-specific digital PCR in the context of cytokine release syndrome. Exp Hematol. 2020;88:7-14.e3.","journal-title":"Exp Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01658-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01658-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T16:05:29Z","timestamp":1655309129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01658-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1038\/s41409-022-01658-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}